首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2016年 9期 肝衰竭 => 肝纤维化及肝硬化 =>恩替卡韦联合扶正化瘀胶囊对代偿期..
恩替卡韦联合扶正化瘀胶囊对代偿期慢性乙型肝炎肝硬化患者炎性因子及纤维化指标的影响
Effect of entecavir combined with Fuzheng Huayu capsules on inflammatory factors and fibrosis markers in patients with compensated chronic hepatitis B-related cirrhosis
文章发布日期:2016年08月08日  来源:  作者:王 贺, 王千钧, 孙风波, 等  点击次数:1200次  下载次数:237次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:目的观察恩替卡韦(ETV)联合扶正化瘀胶囊对代偿期慢性乙型肝炎肝硬化患者的疗效。方法收集2013年1月-2015年12月在青岛市第六人民医院就诊的代偿期慢性乙型肝炎肝硬化患者142例,随机分为治疗组(n=71)和对照组(n=71)。两组均给予保肝、对症等常规治疗,在此基础上,对照组接受恩替卡韦0.5 mg/d治疗,治疗组在对照组治疗基础上联合扶正化瘀胶囊1.5g,口服,2次/d,两组患者均治疗12个月。观察两组患者炎性因子及纤维化指标的变化情况。计量资料组间比较采用t检验,计数资料组间比较采用χ2检验。结果治疗12个月后,治疗组与对照组血清HBV DNA阴转率分别为91.5%(65/71)和901%(64/71),两组之间差异无统计学意义(χ2=0005,P=0.771);治疗组治疗12个月后血清透明质酸、层黏连蛋白、Ⅲ型前胶原、Ⅳ型胶原、AST、ALT、肝脏硬度值、TNFα、IL-6、IL-8和超敏C反应蛋白(hs-CRP)与对照组相比均明显下降(t值分别为16187、5343、13697、17121、7409、27371、7973、5471、7885、9057、8171,P值均<0.001)。结论ETV联合扶正化瘀胶囊治疗相对于单独用ETV治疗代偿期慢性乙型肝炎肝硬化患者能更好的抗纤维化,抑制炎性因子TNF-α、IL-6、IL-8和hs-CRP的释放。
【Abstract】:ObjectiveTo investigate the clinical effect of entecavir (ETV) combined with Fuzheng Huayu capsules in the treatment of patients with compensated chronic hepatitis B-related cirrhosis. MethodsA total of 142 patients with compensated chronic hepatitis B-related cirrhosis who visited the Sixth People′s Hospital Qingdao from January 2013 to December 2015 were randomly divided into treatment group and control group, with 71 patients in each group. Both groups were given conventional treatment such as liver-protecting and symptomatic treatment. The patients in the control group were given ETV 0.5 mg/day, while those in the treatment group received oral administration of Fuzheng Huayu capsules 1.5 g twice a day in addition to the treatment in the control group. Both groups were treated for 12 months. The changes in inflammatory factors and fibrosis markers were observed. The t-test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. ResultsAfter the 12-month treatment, the treatment group and the control group showed no significant difference in the serum HBV DNA clearance rate [91.5% (65/71) vs 90.1% (64/71), P=0.771]. Compared with the control group, the treatment group showed significant reductions in serum hyaluronic acid, laminin, procollagen type III, collagen type IV, alanine aminotransferase, aspartate aminotransferase, liver stiffness measurement, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-8 (IL-8), and hypersensitive C-reactive protein (hs-CRP) (t=16187,5343,13697,17121,7409,27371,7973,5471,7885,9057,8171,all P<0.001). ConclusionCompared with ETV alone, ETV combined with Fuzheng Huayu capsules exerts a better anti-fibrotic effect and can inhibit the release of TNF-α, IL-6, IL-8 and hs-CRP in patients with compensated chronic hepatitis B-related cirrhosis.
【关键字】:肝硬化; 肝炎, 乙型, 慢性; 恩替卡韦; 扶正化瘀胶囊
【Key words】: liver cirrhosis; hepatitis B, chronic; entecavir; Fuzheng Huayu capsule
【引证本文】:王贺, 王千钧, 孙风波, 等. 恩替卡韦联合扶正化瘀胶囊对代偿期慢性乙型肝炎肝硬化患者炎性因子及纤维化指标的影响[J]. 临床肝胆病杂志, 2016, 32(9): 1734-1738.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号